Limits...
Antidiabetic, antioxidant, antihyperlipidemic effect of extract of Euryale ferox salisb. with enhanced histopathology of pancreas, liver and kidney in streptozotocin induced diabetic rats.

Ahmed D, Kumar V, Verma A, Shukla GS, Sharma M - Springerplus (2015)

Bottom Line: The ethanolic extract was supplemented in different doses through oral route.Biochemical investigations were carried out according to previously reported methods.Histopathological examinations were done accordingly.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agriculture, Technology and Sciences (SHIATS)-Deemed University, Allahabad, India.

ABSTRACT

Background: Ethanolic extract of Euryale ferox salisb. (EFx) may have an effect on the activity of hepatic antioxidant enzymes, glycemic control and lipid profile and histopathology of pancreas, liver and kidney of streptozotocin (STZ)-induced diabetic wistar rats.

Methods: Wistar albino rats were divided into eight groups viz. non-diabetic (normal control), diabetic control (STZ-induced), diabetic treated (infused with different doses of Euryale ferox. Salisb. ethanolic extract) and diabetic conventional treated (treated with Glibenclamide). Diabetes was induced by administering streptozotocin (60 mg/kg body weight) intraperitoneal (i.p). The ethanolic extract was supplemented in different doses through oral route. Biochemical investigations were carried out according to previously reported methods. Histopathological examinations were done accordingly.

Results: The EFx supplemented diabetic rats significantly (p < 0.001) decreased the blood glucose level in a dose dependent manner. Plasma insulin level was significantly increased in EFx treated rats. The hepatic gluconeogenic enzymes activities were restored to normal in EFx treated rats. Activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and reduced glutathione (GSH) were significantly increased (p < 0.001) among EFx treated rats. Lipid profile was reinstated to nearly normal level among EFx treated rats. Histopathological investigations revealed that microscopic architecture of pancreatic, hepatic and renal cells improvised in EFx treated diabetic rats.

Conclusion: EFx supplement could improve the glycemic control as well as lipid profile in diabetic rats along with improvised antioxidant enzymes which has beneficial effect in preventing the diabetic complications by scavenging the free radicals in diabetic rats.

No MeSH data available.


Related in: MedlinePlus

Effect of EFx on plasma insulin level at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4489967&req=5

Fig2: Effect of EFx on plasma insulin level at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.

Mentions: The level of plasma insulin was measured at different periods during the experimentation. A significant decrease in the level of plasma insulin was observed in the untreated diabetic rats compared to the normal rats and the level of plasma insulin was further decreased in the untreated diabetic rats at the end of the study i.e. after 45 days. Treatment with the methanol/dichloromethane extract of EFx in a dose dependent manner. Treatment with 400 mg/kg body weight of EFx was shown to produce most significant (p < 0.05) effect on the level of plasma insulin. It amplified the level of plasma insulin nearly to the normal as compared to the other doses of EFx at the end of research exertion (Table 2; Figure 2).Table 2


Antidiabetic, antioxidant, antihyperlipidemic effect of extract of Euryale ferox salisb. with enhanced histopathology of pancreas, liver and kidney in streptozotocin induced diabetic rats.

Ahmed D, Kumar V, Verma A, Shukla GS, Sharma M - Springerplus (2015)

Effect of EFx on plasma insulin level at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4489967&req=5

Fig2: Effect of EFx on plasma insulin level at different time interval of therapy, Group 1: normal control; Group 2: STZ (60 mg/kg i.p.); Group 3: diabetic control + (EFx) (100 mg/kg body weight); Group 4: diabetic control + (EFx) (200 mg/kg body weight) and continue for 45 days; Group5: diabetic + diabetic control + (EFx) (300 mg/kg body weight) and continue for 45 days; Group 6: diabetic control + (EFx) (400 mg/kg body weight) and continue for 45 days; Group 7: diabetic control + glibenclamide (1 mg/kg body weight) and continue for 45 days.
Mentions: The level of plasma insulin was measured at different periods during the experimentation. A significant decrease in the level of plasma insulin was observed in the untreated diabetic rats compared to the normal rats and the level of plasma insulin was further decreased in the untreated diabetic rats at the end of the study i.e. after 45 days. Treatment with the methanol/dichloromethane extract of EFx in a dose dependent manner. Treatment with 400 mg/kg body weight of EFx was shown to produce most significant (p < 0.05) effect on the level of plasma insulin. It amplified the level of plasma insulin nearly to the normal as compared to the other doses of EFx at the end of research exertion (Table 2; Figure 2).Table 2

Bottom Line: The ethanolic extract was supplemented in different doses through oral route.Biochemical investigations were carried out according to previously reported methods.Histopathological examinations were done accordingly.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom Institute of Agriculture, Technology and Sciences (SHIATS)-Deemed University, Allahabad, India.

ABSTRACT

Background: Ethanolic extract of Euryale ferox salisb. (EFx) may have an effect on the activity of hepatic antioxidant enzymes, glycemic control and lipid profile and histopathology of pancreas, liver and kidney of streptozotocin (STZ)-induced diabetic wistar rats.

Methods: Wistar albino rats were divided into eight groups viz. non-diabetic (normal control), diabetic control (STZ-induced), diabetic treated (infused with different doses of Euryale ferox. Salisb. ethanolic extract) and diabetic conventional treated (treated with Glibenclamide). Diabetes was induced by administering streptozotocin (60 mg/kg body weight) intraperitoneal (i.p). The ethanolic extract was supplemented in different doses through oral route. Biochemical investigations were carried out according to previously reported methods. Histopathological examinations were done accordingly.

Results: The EFx supplemented diabetic rats significantly (p < 0.001) decreased the blood glucose level in a dose dependent manner. Plasma insulin level was significantly increased in EFx treated rats. The hepatic gluconeogenic enzymes activities were restored to normal in EFx treated rats. Activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and reduced glutathione (GSH) were significantly increased (p < 0.001) among EFx treated rats. Lipid profile was reinstated to nearly normal level among EFx treated rats. Histopathological investigations revealed that microscopic architecture of pancreatic, hepatic and renal cells improvised in EFx treated diabetic rats.

Conclusion: EFx supplement could improve the glycemic control as well as lipid profile in diabetic rats along with improvised antioxidant enzymes which has beneficial effect in preventing the diabetic complications by scavenging the free radicals in diabetic rats.

No MeSH data available.


Related in: MedlinePlus